Current News

Contact | Print version | PDF version | Send article | RSS feed

New Technology for Accelerating Development of Vaccines Against H5N1 Flu Enters Pilot Study at ProImmune

07 Feb 2006 - Technology that enables scientists to identify targets for the development of vaccines against viruses such as H5N1 in weeks rather than months has entered a pilot study at ProImmune, Oxford, UK.
 
ProImmune has developed REVEAL & ProVE(TM), a novel technology that enables scientists to identify the specific antigens on viruses that can be detected by the immune system and used as targets in vaccine development. The new screening system enables researchers to analyse any protein derived from a pathogen for potential immunogenicity within only four weeks, a process that has previously taken many months to complete. The pilot study will explore the protein sequence of the key H5 protein in the avian influenza virus.